Galena Is Trying To Send A Positive Signal To The Street, Says Roth Capital http://www.smarteranalyst.com/2014/08/21/galena-is-trying-to-send-a-positive-signal-to-the-street-says-roth-capital/

$BCRX BioLineRx: We See Significant Potential Upside In This Name, Says Roth Capital http://www.smarteranalyst.com/2014/08/21/biolinerx-we-see-significant-potential-upside-in-this-name-says-roth-capital/

$BCRX BioLineRx: We See Significant Potential Upside In This Name, Says Roth Capital http://www.smarteranalyst.com/2014/08/21/biolinerx-we-see-significant-potential-upside-in-this-name-says-roth-capital/

$BCRX BioLineRx: We See Significant Potential Upside In This Name, Says Roth Capital http://www.smarteranalyst.com/2014/08/21/biolinerx-we-see-significant-potential-upside-in-this-name-says-roth-capital/

JA Solar: The Stock Is Underappreciated, Says Roth Capital
http://www.smarteranalyst.com/2014/08/21/ja-solar-the-stock-is-underappreciated-says-roth-capital/

$JASO Axiom Maintains Hold On JA Solar But Sees %17 Upside For The Stock http://www.smarteranalyst.com/2014/08/21/axiom-maintains-hold-on-ja-solar-but-sees-upside-for-the-stock/

$JASO Axiom Maintains Hold On JA Solar But Sees %17 Upside For The Stock http://www.smarteranalyst.com/2014/08/21/axiom-maintains-hold-on-ja-solar-but-sees-upside-for-the-stock/

$JASO Axiom Maintains Hold On JA Solar But Sees %17 Upside For The Stock http://www.smarteranalyst.com/2014/08/21/axiom-maintains-hold-on-ja-solar-but-sees-upside-for-the-stock/

$PDLI Cowen Maintains Market Perform On PDL Biopharma Following 2Q14 Update; Raises PT To $8 http://www.smarteranalyst.com/2014/08/20/cowen-maintains-market-perform-on-pdl-biopharma-following-2q14-update-raises-pt-to-8/

$FOLD Amicus: Migalastat Chances For FDA Approval Are Pretty Good, Says Cowens http://www.smarteranalyst.com/2014/08/20/amicus-migalastat-chances-for-fda-approval-are-pretty-good-says-cowen/

$FOLD Janney Capital Sees 42% Upside In Amicus Therapeutics Following Positive Phase 3 Data http://www.smarteranalyst.com/2014/08/20/janney-capital-sees-42-upside-in-amicus-therapeutics-following-positive-phase-3-data/

$FOLD Janney Capital Sees 42% Upside In Amicus Therapeutics Following Positive Phase 3 Data http://www.smarteranalyst.com/2014/08/20/janney-capital-sees-42-upside-in-amicus-therapeutics-following-positive-phase-3-data/

$FOLD Janney Capital Sees 42% Upside In Amicus Therapeutics Following Positive Phase 3 Data http://www.smarteranalyst.com/2014/08/20/janney-capital-sees-42-upside-in-amicus-therapeutics-following-positive-phase-3-data/

Janney Capital Sees 42% Upside In Amicus Therapeutics Following Positive Phase 3 Data http://www.smarteranalyst.com/2014/08/20/janney-capital-sees-42-upside-in-amicus-therapeutics-following-positive-phase-3-data/

$FLML Roth Capital Recommends Purchase Flamel Shares Ahead Of Improving Fundamentals http://www.smarteranalyst.com/2014/08/20/roth-capital-recommends-purchase-flamel-shares-ahead-of-improving-fundamentals/

$FLML Roth Capital Recommends Purchase Flamel Shares Ahead Of Improving Fundamentals http://www.smarteranalyst.com/2014/08/20/roth-capital-recommends-purchase-flamel-shares-ahead-of-improving-fundamentals/

Cantor Reiterates Hold On Ligand Pharmaceuticals, Raises PT To $49 http://www.smarteranalyst.com/2014/08/20/cantor-reiterates-hold-on-ligand-pharmaceuticals-raises-pt-to-49/

$TJX TJX Companies: Shares Are Fairly Valued, Says Canaccord http://www.smarteranalyst.com/2014/08/20/tjx-companies-shares-are-fairly-valued-says-canaccord/

$DKS We Expect Shares To Rebound On The Second-Quarter Results, Says William Blair http://www.smarteranalyst.com/2014/08/20/we-expect-shares-to-rebound-on-the-second-quarter-results-says-william-blair/

Maintains Neutral On SuperValue Following Investor Session; Sees Slight Downside To Shares http://www.smarteranalyst.com/2014/08/20/ubs-maintains-neutral-on-supervalue-following-investor-session-sees-slight-downside-to-shares/

Cannacord Maintains Hold On Magna, Sees Slight Downside Ahead
http://www.smarteranalyst.com/2014/08/20/cannacord-maintains-hold-on-magna-sees-slight-downside-ahead/

$CYTX Roth Capital Reiterates Buy On Cytori After Receving Funding From BARDA http://www.smarteranalyst.com/2014/08/20/roth-capital-reiterates-buy-on-cytori-after-receving-funding-from-barda/

$CYTX Roth Capital Reiterates Buy On Cytori After Receving Funding From BARDA http://www.smarteranalyst.com/2014/08/20/roth-capital-reiterates-buy-on-cytori-after-receving-funding-from-barda/

Roth Capital Reiterates Buy On Cytori After Receving Funding From BARDA http://www.smarteranalyst.com/2014/08/20/roth-capital-reiterates-buy-on-cytori-after-receving-funding-from-barda/

Canaccord Maintains Hold On Cabot Oil & Gas As Constitution Pipeline Delayed http://www.smarteranalyst.com/2014/08/20/canaccord-maintains-hold-on-cabot-oil-gas-as-constitution-pipeline-delayed/

$SRPT Cowen Assumes Coverage Of Sarepta At Outperform, $44 Price Target http://www.smarteranalyst.com/2014/08/18/cowen-assumes-coverage-of-sarepta-at-outperform-44-price-target/

$SRPT Cowen Assumes Coverage Of Sarepta At Outperform, $44 Price Target http://www.smarteranalyst.com/2014/08/18/cowen-assumes-coverage-of-sarepta-at-outperform-44-price-target/

Cowen Assumes Coverage Of Sarepta At Outperform, $44 Price Target http://www.smarteranalyst.com/2014/08/18/cowen-assumes-coverage-of-sarepta-at-outperform-44-price-target/

$FOLD Cowen Rates Amicus A Buy In Transitioned Coverage, $9 Price Target http://www.smarteranalyst.com/2014/08/18/cowen-rates-amicus-a-buy-in-transitioned-coverage-9-price-target/

$FOLD Cowen Rates Amicus A Buy In Transitioned Coverage, $9 Price Target http://www.smarteranalyst.com/2014/08/18/cowen-rates-amicus-a-buy-in-transitioned-coverage-9-price-target/

Cowen Rates Amicus A Buy In Transitioned Coverage, $9 Price Target http://www.smarteranalyst.com/2014/08/18/cowen-rates-amicus-a-buy-in-transitioned-coverage-9-price-target/

Canaccord Maintains Buy On IMAX Following JV Arrangement Expansion With AMC http://www.smarteranalyst.com/2014/08/18/canaccord-maintains-buy-on-imax-following-jv-arrangement-expansion-with-amc/

Wedbush Reiterates Buy On Epizyme Following 2Q14 Update And Positive Early-Stage EPZ-6438 Data http://www.smarteranalyst.com/2014/08/18/35551/

We Remain Positive On O’Reilly Automotive Shares, Says Wedbush http://www.smarteranalyst.com/2014/08/18/we-remain-positive-on-oreilly-automotive-shares-says-wedbush/

Wedbush Maintains Neutral On CarMax Following CAF Data http://www.smarteranalyst.com/2014/08/18/wedbush-maintains-neutral-on-carmax-following-caf-data/

$DLTR Dollar Tree Is Our Favorite Stock In Our Discount Retailer Universe, Says Wedbush http://www.smarteranalyst.com/2014/08/18/dollar-tree-is-our-favorite-stock-in-our-discount-retailer-universe-says-wedbush/

$DLTR Dollar Tree Is Our Favorite Stock In Our Discount Retailer Universe, Says Wedbush http://www.smarteranalyst.com/2014/08/18/dollar-tree-is-our-favorite-stock-in-our-discount-retailer-universe-says-wedbush/

Dollar Tree Is Our Favorite Stock In Our Discount Retailer Universe, Says Wedbush http://www.smarteranalyst.com/2014/08/18/dollar-tree-is-our-favorite-stock-in-our-discount-retailer-universe-says-wedbush/

$SFLY Shutterfly’s Shares Will Continue To Trade, In-Part, On Take-Out Speculation, Says Topeka http://www.smarteranalyst.com/2014/08/18/shutterflys-shares-will-continue-to-trade-in-part-on-take-out-speculation-says-topeka/

$TGTX Roth Capital Reiterates Buy On TG Therapeutics Following Clinical Study Initiation http://www.smarteranalyst.com/2014/08/15/roth-capital-reiterates-buy-on-tg-therapeutics-following-clinical-study-initiation/